| ADTX 0.0127 -2.31% | SOXS 4.72 -5.03% | SPCX 160.95 19.22% | DFNS 0.233 -9.20% | BITO 8.65 0.12% | RUBI 0.4676 -24.62% | TZA 4.16 -2.58% | CAST 1.55 140.68% | AAL 14.98 2.25% | INTC 124.57 6.51% | SPCE 3.91 -31.76% | SHFS 0.276 16.46% | SRXH 0.148 17.65% | NOK 14.795 5.00% | NVDA 205.19 0.16% | BYAH 1.47 40.00% | SPDN 8.81 -0.45% | TQQQ 77.52 1.99% | TSLL 13.59 3.58% | PAVS 0.208 -28.28% | CPOP 0.195 -81.43% | SMCI 30.46 -4.72% | CUPR 3.97 64.73% | VSME 1.69 52.25% | YYGH 0.119 -3.25% | SQQQ 40.04 -1.93% | RKLB 102.39 -10.79% | TSLA 406.43 1.82% | NVD 5.02 -0.40% | WOK 0.0753 -17.70% | SPY 741.75 0.54% | ASTS 82.41 -15.53% | KEEL 5.59 1.27% | ONDS 9.33 -5.09% | SPYM 87.06 0.25% | AMZN 238.55 -1.23% | XLF 53.34 1.37% | SATS 114.08 -10.97% | QQQ 721.34 0.59% | SOFI 16.58 -0.54% | PLUG 2.76 -2.47% | SOXL 234.68 4.77% | GRAB 3.3 -1.49% | DRIP 4.74 -2.47% | AMC 2.34 2.63% | IREN 59.77 5.40% | HKIT 0.5025 -10.11% | RKLZ 3.01 21.37% | RZLV 2.68 5.93% | MARA 14.08 3.45%

Neogen Corporation's Financial Performance and Strategic Moves

Neogen Corporation, trading under NASDAQ:NEOG, is a prominent player in the food and animal safety industry. The company focuses on developing and marketing products dedicated to food safety, animal safety, and genomics. Neogen's competitors include companies like IDEXX Laboratories and Zoetis. Recently, Nassif Mikheal, the director and CEO, purchased 137 shares at $9.33 each, increasing his total holdings to 632 shares.

Neogen's recent financial performance has been noteworthy. The company reported second-quarter fiscal 2026 earnings per share (EPS) of 10 cents and revenues of $224.7 million, both surpassing expectations. This strong performance led to a 31.6% increase in the stock price, as highlighted by Barron's. Despite a 2.8% year-over-year revenue decrease, core revenues grew by 2.9%, offsetting declines from divestitures and discontinued products.

The company has raised its fiscal 2026 guidance, projecting revenues between $845 million and $855 million, with approximately $175 million in adjusted EBITDA. The positive impact of foreign currency contributed 0.9% to the revenue, while divestitures and discontinued product lines negatively impacted it by 6.6%. Neogen's results exceeded the Zacks Consensus Estimate by 7.93%, indicating strong performance and an optimistic outlook.

Neogen's financial metrics reveal a mixed picture. The price-to-sales ratio is approximately 2.35, and the enterprise value to sales ratio is about 3.09, suggesting the market values the company's sales and total valuation, including debt, at a premium. The enterprise value to operating cash flow ratio is high at 41.08, indicating a premium relative to cash flow generation. The debt-to-equity ratio is 0.38, reflecting a low level of debt compared to equity.

The company maintains a strong liquidity position with a current ratio of approximately 3.91, indicating ample current assets to cover liabilities. Neogen's strategic initiatives and strong market position continue to drive investor confidence, as evidenced by the recent stock price surge following the earnings report.

Published on: January 16, 2026